|
||||||||||||||||||||||
![]() |
|
|
|
![]() |
Alternate Title Phase III Randomized, Double-Blind, Placebo-Controlled Study of Finasteride (Proscar) for the Chemoprevention of Prostate Cancer
Trial Description Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known whether finasteride is effective in preventing the recurrence of prostate cancer. Randomized phase III trial to study the effectiveness of finasteride in preventing prostate cancer in patients who are at risk of recurrence.
Final eligibility for a clinical trial is determined by the health professionals conducting the trial. Patients will be randomly assigned to one of two groups. Patients in group one will receive finasteride. Patients in group two will receive a placebo. Important: For more details about this trial, refer to the Health Professional version of the trial summary. If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site. Trial Lead Organizations Southwest Oncology Group
|
![]() |
![]() |
![]() |
![]() |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
![]() A Service of the National Cancer Institute |
![]() |
![]() |